KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Opko Health (OPK) EBITDA (2016 - 2025)

Historic EBITDA for Opko Health (OPK) over the last 16 years, with Q3 2025 value amounting to $48.1 million.

  • Opko Health's EBITDA rose 23804.16% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$112.2 million, marking a year-over-year increase of 4029.32%. This contributed to the annual value of -$152.1 million for FY2024, which is 315.63% up from last year.
  • As of Q3 2025, Opko Health's EBITDA stood at $48.1 million, which was up 23804.16% from -$60.0 million recorded in Q2 2025.
  • Opko Health's EBITDA's 5-year high stood at $48.1 million during Q3 2025, with a 5-year trough of -$87.8 million in Q3 2022.
  • In the last 5 years, Opko Health's EBITDA had a median value of -$55.3 million in 2022 and averaged -$31.4 million.
  • As far as peak fluctuations go, Opko Health's EBITDA plummeted by 97786.48% in 2024, and later skyrocketed by 23804.16% in 2025.
  • Opko Health's EBITDA (Quarter) stood at -$63.1 million in 2021, then grew by 12.39% to -$55.3 million in 2022, then fell by 24.93% to -$69.0 million in 2023, then soared by 52.0% to -$33.1 million in 2024, then soared by 245.01% to $48.1 million in 2025.
  • Its EBITDA was $48.1 million in Q3 2025, compared to -$60.0 million in Q2 2025 and -$67.2 million in Q1 2025.